ERBB2 and neoplasm: The proportion of HER2-low and HER2-0 tumors were not the same between HR+ and HR– eBC: 171 of HR+ tumor (61%), and 65 of HR– tumors (28%) were HER2-low (CONSORT diagram, Fig. 1).